InvestorsHub Logo
Post# of 251701
Next 10
Followers 56
Posts 1150
Boards Moderated 0
Alias Born 11/12/2005

Re: poorgradstudent post# 123513

Monday, 07/18/2011 12:23:57 PM

Monday, July 18, 2011 12:23:57 PM

Post# of 251701

My impression was that there was indeed some element of review and back/forth during the rolling submission process.



That's how rolling review was intended, but every company we've spoken with (n=dozen or so) has said they received nothing from the FDA except for an acknowledgement the file/truck o' paper was received. A couple of companies said they were notified the materials appeared to be complete, "subject to detailed review", but most didn't receive that.

It could be with our small sample size I'm getting the wrong impression, but I don't think so. The FDA has apparently indicated they don't want to waste scarce review time until the app is complete and, importantly, finalized. They don't want to review a submitted piece that might be changed later when the whole app is finalized. they also don't want to waste review time on an app that might never be complete.

Unless otherwise indicated, this is the personal viewpoint of David
Miller and not necessarily that of Biotech Stock Research, LLC.
We're on Twitter at BiotechStockRsr

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.